H Sevim1, J F Parkinson, K L McDonald. 1. Cure for Life Foundation Neuro-oncology Laboratory, Adult Cancer Program, Lowy Cancer Research Centre, Prince of Wales Clinical School, University of NSW, Sydney, NSW, Australia.
Abstract
BACKGROUND: Treatments which significantly improve progression-free and overall survival for patients with relapsed glioblastoma (GBM) after the standard therapy are lacking. The Topoisomerase II (TopoII) enzyme is a key target of anticancer agents because of the important role it plays in transcription regulation and chromatin remodeling. A drug with strong topoisomerase-mediated anticancer activity is etoposide that is used in combination with carboplatin in patients with relapsed GBM. We hypothesized that tumors harboring high expression of TopoII alpha (TopoIIa) would be more sensitive to etoposide treatment. METHODS: The relative expression levels of TopoIIa protein were measured in a panel of GBM cell lines using Western blot analysis and in a cohort of GBM using immunohistochemistry. Expression levels of TopoIIa in the cell lines were correlated with relative sensitivity to treatment with etoposide. To ascertain the role TopoIIa plays in mediating response to etoposide, expression was reduced with a siRNA targeted to TopoIIa. RESULTS: Protein expression of TopoIIa, although high in the cell lines, was very low in patient specimens. Correlations between TopoIIa protein expression and sensitivity to etoposide were evident. The IC(50) for the low-TopoIIa-expressing cell line, T98G, was almost 50 times higher than M059K (high TopoIIa). Inhibition of TopoIIa in MO59K cells with siRNA significantly altered the IC(50), increasing the resistance to etoposide. Interestingly, the expression of TopoIIa was not decreased after treatment with etoposide, indicating other mechanisms underplay treatment response. CONCLUSIONS: In vitro, the levels of TopoIIa protein expression correlate with response to etoposide but also multiple molecular events namely DNA-PK and MDR also play a role in cell sensitivity to etoposide. That we did not find a high expression of TopoIIa in clinical specimens further suggests the mechanisms underlying treatment response are complex.
BACKGROUND: Treatments which significantly improve progression-free and overall survival for patients with relapsed glioblastoma (GBM) after the standard therapy are lacking. The Topoisomerase II (TopoII) enzyme is a key target of anticancer agents because of the important role it plays in transcription regulation and chromatin remodeling. A drug with strong topoisomerase-mediated anticancer activity is etoposide that is used in combination with carboplatin in patients with relapsed GBM. We hypothesized that tumors harboring high expression of TopoII alpha (TopoIIa) would be more sensitive to etoposide treatment. METHODS: The relative expression levels of TopoIIa protein were measured in a panel of GBM cell lines using Western blot analysis and in a cohort of GBM using immunohistochemistry. Expression levels of TopoIIa in the cell lines were correlated with relative sensitivity to treatment with etoposide. To ascertain the role TopoIIa plays in mediating response to etoposide, expression was reduced with a siRNA targeted to TopoIIa. RESULTS: Protein expression of TopoIIa, although high in the cell lines, was very low in patient specimens. Correlations between TopoIIa protein expression and sensitivity to etoposide were evident. The IC(50) for the low-TopoIIa-expressing cell line, T98G, was almost 50 times higher than M059K (high TopoIIa). Inhibition of TopoIIa in MO59K cells with siRNA significantly altered the IC(50), increasing the resistance to etoposide. Interestingly, the expression of TopoIIa was not decreased after treatment with etoposide, indicating other mechanisms underplay treatment response. CONCLUSIONS: In vitro, the levels of TopoIIa protein expression correlate with response to etoposide but also multiple molecular events namely DNA-PK and MDR also play a role in cell sensitivity to etoposide. That we did not find a high expression of TopoIIa in clinical specimens further suggests the mechanisms underlying treatment response are complex.
Authors: Nabanita Patra; Umasankar De; Jin-Ah Kang; Ji Mim Kim; Mee Young Ahn; Jaewon Lee; Jee H Jung; Hae Young Chung; Hyung Ryong Moon; Hyung Sik Kim Journal: Eur J Pharmacol Date: 2011-03-01 Impact factor: 4.432
Authors: Patrick Y Wen; W K Alfred Yung; Kathleen R Lamborn; Patricia L Dahia; Yanfeng Wang; Bin Peng; Lauren E Abrey; Jeffrey Raizer; Timothy F Cloughesy; Karen Fink; Mark Gilbert; Susan Chang; Larry Junck; David Schiff; Frank Lieberman; Howard A Fine; Minesh Mehta; H Ian Robins; Lisa M DeAngelis; Morris D Groves; Vinay K Puduvalli; Victor Levin; Charles Conrad; Elizabeth A Maher; Kenneth Aldape; Michael Hayes; Laurie Letvak; Merrill J Egorin; Renaud Capdeville; Richard Kaplan; Anthony J Murgo; Charles Stiles; Michael D Prados Journal: Clin Cancer Res Date: 2006-08-15 Impact factor: 12.531
Authors: W K Alfred Yung; James J Vredenburgh; Timothy F Cloughesy; Phioanh Nghiemphu; Barbara Klencke; Mark R Gilbert; David A Reardon; Michael D Prados Journal: Neuro Oncol Date: 2010-07-08 Impact factor: 12.300
Authors: Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine Journal: J Clin Oncol Date: 2010-02-01 Impact factor: 44.544
Authors: Antje Wick; Christina Pascher; Wolfgang Wick; Tanja Jauch; Michael Weller; Ulrich Bogdahn; Peter Hau Journal: J Neurol Date: 2009-02-25 Impact factor: 4.849
Authors: Nathalie Wong; Winnie Yeo; Wai-Lap Wong; Navy L-Y Wong; Kathy Y-Y Chan; Frankie K-F Mo; Jane Koh; Stephan Lam Chan; Anthony T-C Chan; Paul B-S Lai; Arthur K-K Ching; Joanna H-M Tong; Ho-Keung Ng; Philip J Johnson; Ka-Fai To Journal: Int J Cancer Date: 2009-02-01 Impact factor: 7.396
Authors: Adam M Sonabend; Arthur S Carminucci; Benjamin Amendolara; Mukesh Bansal; Richard Leung; Liang Lei; Ronald Realubit; Hai Li; Charles Karan; Jonathan Yun; Christopher Showers; Robert Rothcock; Jane O; Andrea Califano; Peter Canoll; Jeffrey N Bruce Journal: Neuro Oncol Date: 2014-03-16 Impact factor: 12.300
Authors: Marike W van Gisbergen; Marcus Cebula; Jie Zhang; Astrid Ottosson-Wadlund; Ludwig Dubois; Philippe Lambin; Kenneth D Tew; Danyelle M Townsend; Guido R M M Haenen; Marie-José Drittij-Reijnders; Hisao Saneyoshi; Mika Araki; Yuko Shishido; Yoshihiro Ito; Elias S J Arnér; Hiroshi Abe; Ralf Morgenstern; Katarina Johansson Journal: Mol Pharm Date: 2016-04-28 Impact factor: 4.939